According to the market research, the sales value of Ruxolitinib in China has increased year by year from 2017 to 2020, with the highest growth rate of Ruxolitinib in 2020 (4030%). The sales value of Ruxolitinib in China reached CNY75.56 million in 2020. The main reason is that Ruxolitinib was included in the national medical insurance in China at the end of 2019, which led to the growth of sales and sales volume. In addition, the research found that Ruxolitinib has the potential to accelerate the recovery of patients with new coronary pneumonia and reduce the demand for intensive care and mechanical ventilation. Therefore, with the COVID-19 epidemic in 2020, the sales of Ruxolitinib have increased significantly. The CAGR of the sales value of Ruxolitinib from 2017 to 2020 is 1136.15% in China.
The analyst predicts that with the increase in the number of indications, the sales of Ruxolitinib in the Chinese market will continue to grow from 2021 to 2025. The specific indications of Ruxolitinib vary from country to country. Ruxolitinib has been approved for the treatment of MF patients in 101 countries, and also it has been approved for the treatment of PV patients in more than 75 countries. At present, China has only approved Ruxolitinib for the treatment of moderate to high-risk MF patients. Therefore, China's Ruxolitinib is suitable for the treatment of patients with MF. Due to the growth of indications in Ruxolitinib in China, the market will also expand and sales will continue to rise.
- The impact of COVID-19 on China's Ruxolitinib market
- Sales value of China's Ruxolitinib 2016-2020
- Competitive landscape of China's Ruxolitinib market
- Prices of Ruxolitinib in China
- Prices of Ruxolitinib in China by regions and manufacturers
- Analysis of factors affecting the development of China's Ruxolitinib market
- Prospect of China's Ruxolitinib market from 2021 to 2025
1.1 Indications for Ruxolitinib
1.2 Development of Ruxolitinib in China
1.3 Governmental Approval of Ruxolitinib in China
1.4 The Impact of COVID-19 on Ruxolitinib market in China
2 Sales of Ruxolitinib in China, 2017-2020
2.1 Sales Value of Ruxolitinib
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Ruxolitinib
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Ruxolitinib by Dosage Form in China, 2017-2020
2.3.2 Analysis of Other Dosage Forms
3 Analysis of Major Ruxolitinib Manufacturers in China, 2017-2020
3.1 Analysis of Market Share of Major Ruxolitinib Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Novartis Pharma Schweiz AG
3.2.1 Enterprise Profile
3.2.2 Sales of JAKAVI (Novartis Pharma Schweiz AG's Ruxolitinib) in China
4 Prices of Ruxolitinib for Different Manufacturers in China, 2020-2021
4.1 Novartis Pharma Schweiz AG (JAKAVI)
4.2 Analysis of Other Enterprises
5 Prospect of Chinese Ruxolitinib drug Market, 2021-2025
5.1 Influential Factors of Chinese Ruxolitinib Market Development
5.1.1 The Impact of COVID-19 on Chinese Ruxolitinib Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
List of Charts
Chart Patent Information About Ruxolitinib Tablets Registration in China
Chart Sales Value of Ruxolitinib Tablets over the World
Chart Sales Value of Ruxolitinib Tablets in China, 2017-2020
Chart Sales Value of Ruxolitinib Tablets in China by Region, 2017-2020
Chart Sales Volume of Ruxolitinib Tablets in China, 2017-2020
Chart Sales Volume of Ruxolitinib Tablets in China by Region, 2017-2020
Chart Market Share by Sales Value of Top Ruxolitinib Manufacturers in China, 2017-2020
Chart Sales Value and Volume of JAKAVI in China, 2017-2020
Chart Referential Prices of JAKAVI in China, 2020-2021
Chart Forecast on Sales Value of Ruxolitinib in China, 2021-2025
Chart Forecast on Sales Volume of Ruxolitinib in China, 2021-2025
- Novartis Pharma Schweiz AG
Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.
Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.
Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.
The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.
The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.
1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.